Gemphire Therapeutics (GEMP): Gearing up for three Phase 2 read outs in 2017 - RBC

RBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Gemphire Therapeutics (NASDAQ: GEMP) along with the price target of $25.00.

Over the next few months, three planned Phase 2 studies will start and continue to enroll patients with HoFH, HeFH/ASCVD and SHTG. As Phase 2 data gets top-lined in 2017, the market will be set up for important inflection points.

For an analyst ratings summary and ratings history on Gemphire Therapeutics click here. For more ratings news on Gemphire Therapeutics click here.

Shares of Gemphire Therapeutics closed at $11.21 yesterday.

You May Also Be Interested In

• Amazon.com (AMZN) PT Raised to $215 at UBS
• Near-term rate cut even less likely following today's data - ING
• Premier Financial Corp. (PFC) PT Raised to $22 at Piper Sandler